Harry L A Janssen

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression
    Harry L A Janssen
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Hepatol 39:414-20. 2003
  2. ncbi request reprint Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Dr Molewaterplein 40, Room Ca 326, 3015 GD Rotterdam, The Netherlands
    Hepatology 39:804-10. 2004
  3. ncbi request reprint Coarse vs. fine needle aspiration biopsy
    Dave Sprengers
    J Hepatol 41:503-4; author reply 504. 2004
  4. doi request reprint Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
    Bart J Veldt
    Erasmus MC University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
    Hepatology 47:1856-62. 2008
  5. doi request reprint Immunology of hepatitis B and hepatitis C virus infections
    Andre Boonstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1049-61. 2008
  6. pmc New approaches in the management of chronic hepatitis B: role of tenofovir
    Jurriën Gp Reijnders
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, The Netherlands
    Infect Drug Resist 2:13-26. 2009
  7. pmc Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam s Gravendijkwal 230, Rm Ha 204, 3015 CE Rotterdam, The Netherlands
    Clin Infect Dis 56:100-5. 2013
  8. ncbi request reprint Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
    Lancet 365:123-9. 2005
  9. ncbi request reprint Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response
    Martijn J ter Borg
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
    Hepatology 44:721-7. 2006
  10. ncbi request reprint Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
    Liver Int 26:399-405. 2006

Detail Information

Publications114 found, 100 shown here

  1. ncbi request reprint Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression
    Harry L A Janssen
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Hepatol 39:414-20. 2003
    ..Thus, the aims of this study were to examine the effects of HBV replication on TRAIL cytotoxicity...
  2. ncbi request reprint Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Dr Molewaterplein 40, Room Ca 326, 3015 GD Rotterdam, The Netherlands
    Hepatology 39:804-10. 2004
    ..Our results indicate that after correction for baseline factors, response to IFN therapy increases survival and reduces the risk of developing HCC...
  3. ncbi request reprint Coarse vs. fine needle aspiration biopsy
    Dave Sprengers
    J Hepatol 41:503-4; author reply 504. 2004
  4. doi request reprint Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
    Bart J Veldt
    Erasmus MC University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
    Hepatology 47:1856-62. 2008
    ..013). Multivariate Cox regression analysis of patients with Ishak 6 cirrhosis showed that diabetes mellitus was independently associated with the development of HCC (hazard ratio, 3.28; 95% CI, 1.35-7.97; P = 0.009)...
  5. doi request reprint Immunology of hepatitis B and hepatitis C virus infections
    Andre Boonstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1049-61. 2008
    ....
  6. pmc New approaches in the management of chronic hepatitis B: role of tenofovir
    Jurriën Gp Reijnders
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, The Netherlands
    Infect Drug Resist 2:13-26. 2009
    ....
  7. pmc Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam s Gravendijkwal 230, Rm Ha 204, 3015 CE Rotterdam, The Netherlands
    Clin Infect Dis 56:100-5. 2013
    ..We related occurrence of flares to presence of precore (PC) and/or basal core promoter (BCP) mutants and studied kinetics of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels during flares...
  8. ncbi request reprint Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
    Lancet 365:123-9. 2005
    ..Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response...
  9. ncbi request reprint Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response
    Martijn J ter Borg
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
    Hepatology 44:721-7. 2006
    ..Since there was a considerable response, even in patients with a late or posttreatment decline pattern, prediction of response based on viral decline during the first months of therapy was difficult...
  10. ncbi request reprint Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine
    Monika van Zonneveld
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
    Liver Int 26:399-405. 2006
    ..Liver biopsies were taken before and at the end of treatment. All biopsies were blinded and scored according to the Ishak system...
  11. doi request reprint Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 142:513-520.e1. 2012
    ..A limited number of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B respond to treatment with peginterferon alfa (PEG-IFN). We investigated whether IL28B genotypes are associated with response...
  12. doi request reprint Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 135:459-67. 2008
    ....
  13. ncbi request reprint Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Room L 455, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Hepatol 43:45-52. 2005
    ..To determine which immune cells contribute to HBV-clearance during antiviral therapy, we performed a longitudinal analysis of intrahepatic immune cells during interferon-alpha therapy of chronic HBV-patients using the FNAB technique...
  14. doi request reprint Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Hepatology 56:67-75. 2012
    ..90, 95% confidence interval [CI]: 1.15-7.31, P = 0.023) and HBsAg clearance (OR 5.58, 95% CI: 1.26-24.63, P = 0.013) and patients with non-A genotypes with detectable mutants had a low probability of response...
  15. doi request reprint A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B
    Vincent Rijckborst
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Am J Gastroenterol 105:1762-9. 2010
    ..Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients are at high risk of treatment relapse after any antiviral therapy. Combining peginterferon alpha-2a with ribavirin might improve sustained response rates...
  16. doi request reprint Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Antivir Ther 17:9-17. 2012
    ..We compared HBsAg decline across HBV genotypes between combined responders (HBeAg loss and HBV DNA<10,000 copies/ml at week 78), HBeAg responders (HBeAg loss with HBV DNA>10,000 copies/ml) and non-responders...
  17. doi request reprint Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 137:2002-9. 2009
    ..We analyzed data from the 2 largest global trials of hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B to determine which are most likely to respond to PEG-IFN-alfa therapy...
  18. doi request reprint Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam 3015 CE, The Netherlands
    Am J Gastroenterol 104:2449-57. 2009
    ..The aim of this study was to determine whether a long-term response to PEG-IFN is dependent on the timing of HBeAg loss...
  19. doi request reprint Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
    Vincent Rijckborst
    Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Hepatology 52:454-61. 2010
    ..Quantitative serum HBsAg in combination with HBV DNA enables on-treatment adjustments of peginterferon therapy for HBeAg-negative CHB...
  20. ncbi request reprint Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype
    Hajo J Flink
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Am J Gastroenterol 101:297-303. 2006
    ..In this study, we investigated the frequency of HBsAg loss after treatment with pegylated (Peg)-interferon alpha-2b...
  21. ncbi request reprint The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection
    Wilhelmus F Leemans
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 44:507-11. 2006
    ..To determine the response to pegylated interferon-alpha treatment of HBeAg-positive hepatitis B patients with proven lamivudine resistance...
  22. ncbi request reprint Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV
    Roeland Zoutendijk
    Department of Gastroenterology and Hepatology, University Medical Center, Rotterdam, The Netherlands
    J Infect Dis 206:974-80. 2012
    ..Knowledge about the value of HBsAg levels in patients coinfected with HBV and human immunodeficiency virus (HIV) is lacking...
  23. doi request reprint Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 204, Rotterdam, The Netherlands
    J Hepatol 52:493-500. 2010
    ..Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited...
  24. ncbi request reprint Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 139:491-8. 2010
    ..We studied the long-term durability of nucleos(t)ide analogue-induced HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection...
  25. doi request reprint Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Clin Immunol 129:419-27. 2008
    ..Our data suggest that the higher proportion of intrahepatic Treg observed in patients with a high viral load may explain the lack of control of viral replication...
  26. doi request reprint Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
    Roeland Zoutendijk
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gut 62:760-5. 2013
    ..Entecavir (ETV) is a potent inhibitor of viral replication in chronic hepatitis B and prolonged treatment may result in regression of fibrosis. The aim of this study was to investigate the effect of ETV on disease progression...
  27. doi request reprint Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
    Milan J Sonneveld
    Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Hepatology 52:1251-7. 2010
    ..In a representative subset of 149 patients similar results were found for prediction through long-term (mean 3.0 years) follow-up...
  28. doi request reprint Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Best Pract Res Clin Gastroenterol 22:1093-108. 2008
    ..Aiming for sustained response is of particular interest because many HBV-infected patients are in need of antiviral therapy at a young age and may otherwise require indefinite antiviral therapy...
  29. doi request reprint Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
    Joep de Bruijne
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Hepatology 52:1590-9. 2010
    ..Narlaprevir (with or without ritonavir) alone or in combination with PEG-IFN-α-2b was safe and well tolerated...
  30. ncbi request reprint Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
    Bart J Veldt
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Ann Intern Med 147:677-84. 2007
    ..Clinical outcomes of chronic hepatitis C infection in patients with advanced fibrosis include liver failure, hepatocellular carcinoma, and death...
  31. doi request reprint Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Hepatology 58:872-80. 2013
    ..HBV genotype-specific stopping-rules may be considered at week 12, but treatment discontinuation is indicated in all patients with HBsAg >20,000 IU/mL at week 24, irrespective of HBV genotype...
  32. ncbi request reprint Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial
    Andrea M Woltman
    Department of Gastroenterology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Antivir Ther 14:809-18. 2009
    ..The present dose-escalating randomized placebo-controlled Phase I/II trial aimed to investigate antiviral activity and safety of alpha-GalCer as a novel class of treatment for chronic hepatitis B patients...
  33. ncbi request reprint Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, s Gravendijkwal 230, Room Ca 326, 3015 CE Rotterdam, The Netherlands
    Virology 361:141-8. 2007
    ..The production of IL10 did not decrease during therapy. In conclusion, adefovir induced viral load reduction results in a decline of circulating Treg together with a partial recovery of the immune response...
  34. doi request reprint Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, s Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    J Hepatol 50:674-83. 2009
    ..We investigated the efficacy of entecavir in lamivudine-experienced and -naïve patients with persistently high HBV DNA during adefovir treatment...
  35. doi request reprint Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
    Vincent Rijckborst
    Dept of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 56:1006-11. 2012
    ..We aimed at validating this stopping rule in two independent trials...
  36. doi request reprint Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants
    Milan J Sonneveld
    Departments of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Antiviral Res 97:312-7. 2013
    ..848). The relationship between HBeAg levels and response to PEG-IFN depends upon the presence of PC/BCP mutants. HBeAg levels should therefore not be routinely used to select patients for PEG-IFN, nor for monitoring of therapy...
  37. doi request reprint Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis
    Mark A A Claassen
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, s Gravendijkwal 230, Rotterdam, The Netherlands
    J Hepatol 52:315-21. 2010
    ..However, little is known about Treg present in livers of HCV-infected patients, their association with clinical parameters, and immunopathology resulting in disease progression...
  38. ncbi request reprint Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders
    Vincent Rijckborst
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur J Gastroenterol Hepatol 24:1012-9. 2012
    ..Peginterferon (PEG-IFN) is considered as a first-line treatment option for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. We aimed to evaluate the long-term response to PEG-IFN in HBeAg-negative patients...
  39. doi request reprint Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation
    Waqar R R Farid
    Department of Surgery and Laboratory of Experimental Transplantation and Intestinal Surgery, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Liver Transpl 18:290-7. 2012
    ..HDmiRs are promising candidates as early, stable, and sensitive biomarkers of rejection and hepatic injury after liver transplantation...
  40. ncbi request reprint Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders
    Jilling F Bergmann
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Liver Int 27:1217-25. 2007
    ....
  41. doi request reprint Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands
    Hepatology 55:1673-83. 2012
    ..Cotreatment of MPA with IFN-α resulted in additive effects on ISG expression and enhanced IFN-induced luciferase reporter activity. Knockdown of IRF1, but not IFITM3, significantly attenuated the inhibition of HCV replication by MPA...
  42. ncbi request reprint Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 46:388-94. 2007
    ..Because PEG-IFN therapy results in a high rate of sustained off-therapy response, patients with advanced fibrosis or cirrhosis but compensated liver disease should not be excluded from PEG-IFN treatment...
  43. doi request reprint PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function
    Lianne van de Laar
    Departments of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Blood 120:4982-91. 2012
    ..Manipulation of this pathway or its downstream targets could be used to improve the generation and function of pDCs to augment immunity...
  44. doi request reprint Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B
    Milan J Sonneveld
    Department of Gastroenterology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Hepatol 58:898-903. 2013
    ..Serum levels of interferon-gamma inducible protein 10 (IP-10) are a marker for immune activity, and may predict response to peginterferon (PegIFN) therapy in chronic hepatitis B...
  45. doi request reprint Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 54:449-54. 2011
    ..We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B virus (HBV) infection during peginterferon (PEG-IFN) and entecavir (ETV) monotherapy...
  46. doi request reprint Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
    Robert Roomer
    Department of Gastroenterology and Hepatology, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 52:1225-31. 2010
    ..01) and baseline hyperglycemia (OR 2.17, 95% CI 1.15-4.10, P = 0.016) were associated with an increased risk of infection during HCV treatment. Cirrhosis and chronic obstructive pulmonary disease were not risk factors for infection...
  47. doi request reprint Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic hepatitis B patients
    Arjan Boltjes
    Liver Unit, Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Mol Immunol 53:72-8. 2013
    ..Our findings demonstrate that, although ribavirin does not lead to a viral load decline, in vivo treatment with ribavirin affects the activation of pDC and mDC in chronic HBV patients...
  48. ncbi request reprint Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans
    Dave Sprengers
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Hepatol 45:182-9. 2006
    ..In this study we aimed to characterize the virus-specific CD8 + T-cell response in the liver of patients with acute HBV infection using fine-needle aspiration-biopsy (FNAB)...
  49. ncbi request reprint Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Am J Gastroenterol 101:83-90. 2006
    ..The aim of the present study was to investigate etiology, treatment options, and prognosis of patients with BCS-PVT...
  50. ncbi request reprint Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    Hum Pathol 37:332-8. 2006
    ..01). In conclusion, patients with HCC have an aberrant composition of the DC population in their hepatic LNs. This may be one of the causes of the inadequate T-cell response against HCC in these patients...
  51. ncbi request reprint Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C
    Robert Roomer
    Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Antivir Ther 16:771-4. 2011
    ..The aim of this study was to assess discordance between the week 24 HCV RNA test results of two PCR-based assays (Amplicor and TaqMan) and the transcription-mediated amplification (TMA) HCV RNA qualitative assay...
  52. doi request reprint HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo
    Bettina E Hansen
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Med Virol 83:1917-23. 2011
    ..The decline of HBV DNA was greater in patients with HBeAg loss or who exhibited an ALT flare during PEG-IFN than in patients with spontaneous HBeAg loss or flares during placebo therapy...
  53. doi request reprint Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C
    Claudia Verveer
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
    Liver Int 32:622-8. 2012
    ..We prospectively studied the performance of TE compared to histology and also whether there are differences between CHB and CHC. Only large biopsies (≥ 25 mm) were used...
  54. ncbi request reprint Intrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    J Med Virol 72:215-22. 2004
    ..Response to therapy led to a significant reduction of intrahepatic CD8 T-lymphocytes. Co-localisation of CD8 T-lymphocytes and HBcAg-positive hepatocytes suggests antiviral activity predominantly at the site of maximum HBV replication...
  55. doi request reprint External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study
    Edith M Koehler
    Department of Gastroenterology and Hepatology, Erasmus MC University Hospital, Rotterdam, The Netherlands
    Clin Gastroenterol Hepatol 11:1201-4. 2013
    ..We calculated its ability to identify fatty liver disease from any cause or nonalcoholic fatty liver disease (NAFLD) in a large population of white elderly persons...
  56. doi request reprint A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Clin Virol 51:175-8. 2011
    ..Currently, 2 commercial platforms are available for HBsAg quantification in clinical practice, the Architect HBsAg QT and the Elecsys HBsAg. We aimed to directly compare the results of these assays...
  57. doi request reprint Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Antivir Ther 17:1605-8. 2012
    ..However, prolonged nucleoside/nucleotide analogue therapy may result in comparable serological response rates as with PEG-IFN...
  58. ncbi request reprint Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV
    Renate G van der Molen
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 44:907-14. 2006
    ..Our findings provide clues for the reasons why current antiviral therapy does not lead to consistently sustained viral eradication...
  59. doi request reprint Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response
    Roeland Zoutendijk
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 54:443-51. 2011
    ..ETV was safe and did not affect renal function or cause lactic acidosis...
  60. doi request reprint Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Liver Transpl 16:520-6. 2010
    ..Therefore, no further mechanistic arguments have been found to break the clinical controversy about the choice of calcineurin inhibitors during posttransplantation antiviral therapy...
  61. doi request reprint Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
    Robert Roomer
    Department of Gastroenterology and Hepatology, Erasmus Medical Center University Medical Center, Rotterdam, The Netherlands
    Antivir Ther 17:509-17. 2012
    ..The aims of the study were to assess safety, tolerability and virological response in patients who were previous PEG-IFN-α/ribavirin non-responders...
  62. doi request reprint Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi)
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Gut 61:1330-9. 2012
    ..A study was undertaken to investigate whether vector-delivered RNAi can transfer between hepatic cells in vitro and in mice, and whether this exchange could extend the therapeutic effect of RNAi against HCV infection...
  63. ncbi request reprint Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients
    Annemiek A van der Eijk
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Eur J Gastroenterol Hepatol 17:1173-9. 2005
    ..In a new approach, we evaluated quantitative HBV DNA content in serum, saliva and urine as a first step in exploring possible modes of horizontal transmission...
  64. pmc Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection
    Eric T T L Tjwa
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
    J Virol 86:4102-9. 2012
    ..Enhancing this reciprocal interaction could reinforce the innate and thus the adaptive T cell response, and this may be an important step in achieving effective antiviral immunity...
  65. ncbi request reprint Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
    Bettina E Hansen
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Med Virol 82:1135-42. 2010
    ..The model strongly supports individual decision making on treatment (dis)continuation in patients with HBeAg positive chronic hepatitis B. It is recommended that PEG-IFN treatment is stopped by 24 weeks if HBV DNA declined <2 log(10)...
  66. ncbi request reprint Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies
    Luc J W van der Laan
    Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Virol Methods 142:189-97. 2007
    ..The minimally invasive fine-needle biopsy provides a useful alternative for regular-needle biopsy for monitoring intrahepatic antiviral responses during therapy...
  67. doi request reprint Virus-drug interactions--molecular insight into immunosuppression and HCV
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, 3015 CE Rotterdam, The Netherlands
    Nat Rev Gastroenterol Hepatol 9:355-62. 2012
    ..Potential implications for clinical practice and future drug development are discussed...
  68. doi request reprint Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus
    Theodora E M S de Vries-Sluijs
    Department of Internal Medicine Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Gastroenterology 139:1934-41. 2010
    ..We investigated the long-term efficacy and renal safety of tenofovir disoproxil fumarate (TDF), administered to patients co-infected with human immunodeficiency virus and hepatitis B virus (HBV) as part of an antiretroviral therapy...
  69. ncbi request reprint Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC Rotterdam, The Netherlands
    Hepatology 46:699-705. 2007
    ..Because chronic HBV patients are known to produce less TNF-alpha, these data implicate an important role for TNF-alpha in the impaired antiviral response in chronic HBV...
  70. pmc Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Mol Med (Berl) 87:713-22. 2009
    ..In conclusion, RNAi and IFN-alpha can be effectively combined without cross-interference and may represent a promising combinational strategy for the treatment of hepatitis C...
  71. doi request reprint Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection
    Qiuwei Pan
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    FEBS Lett 585:1025-30. 2011
    ..Our findings extend the caution of potential off-target effects of lentiviral shRNA libraries which appear unsuitable to screen microRNA regulated phenotypes, such as HCV replication...
  72. ncbi request reprint Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine
    Hajo J Flink
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Am J Gastroenterol 101:2523-9. 2006
    ..e., loss of HBeAg at the end of follow-up) of peginterferon alfa-2b (Peg-IFN alpha2b) in patients who failed to respond to previous courses of standard interferon (IFN) or lamivudine...
  73. doi request reprint The response to TLR ligation of human CD16⁺CD14⁻ monocytes is weakly modulated as a consequence of persistent infection with the hepatitis C virus
    Cheng Peng
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Mol Immunol 48:1505-11. 2011
    ....
  74. doi request reprint The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells
    Marjoleine L Op den Brouw
    Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
    Virology 393:84-90. 2009
    ..These data suggest that in HBV infected patients, MR-mediated interaction between HBsAg and DC and subsequent impairment of DC predominantly occurs at the main site of infection, the liver...
  75. ncbi request reprint Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent
    Annemiek A van der Eijk
    Department of Hepatology and Gastroenterology, Erasmus MC, University Medical Centre, Room Ca 326, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    J Clin Virol 29:92-4. 2004
    ..After intensive source and contact tracing 20 % of acute Hepatitis B virus (HBV) infections remain unexplained. Saliva may be an unexpected vehicle of HBV DNA transmission...
  76. ncbi request reprint Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12
    Bi Sheng Liu
    Liver Unit, Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Eur J Immunol 42:2431-40. 2012
    ..Therefore, type I and III IFNs induce a suboptimal activation of immune cells. These findings are relevant for the development of strategies to further improve IFN-based therapy for patients with multiple sclerosis or viral hepatitis...
  77. pmc Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus
    Marjoleine L Op den Brouw
    Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
    Immunology 126:280-9. 2009
    ..The direct immune regulatory effect of HBV and circulating HBsAg particles on the function of DC can be considered as part of the mechanism by which HBV escapes immunity...
  78. ncbi request reprint Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Centre, and Virology, Erasmus University, Rotterdam, The Netherlands
    Eur J Gastroenterol Hepatol 16:801-7. 2004
    ..The efficacy of new generation nucleoside analogues should be further elucidated in future studies...
  79. doi request reprint Experimental models for hepatitis C viral infection
    Andre Boonstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 50:1646-55. 2009
    ..In this article, we give an overview of current models, discuss their limitations, and provide future perspectives for research directed at the prevention and cure of hepatitis C...
  80. ncbi request reprint Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection
    Jan M Vrolijk
    Department of Hepatology and Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Infect Dis 188:1528-32. 2003
    ..Neither peripheral cytokine levels nor HCV-specific T cell reactivity in peripheral blood mononuclear cells showed a relationship to response to therapy...
  81. ncbi request reprint The intrahepatic immune response during chronic hepatitis B infection can be monitored by the fine-needle aspiration biopsy technique
    Thjon J Tang
    Department of Gastroenterology and Hepatology, Room L 455, Erasmus MC, University Medical Center Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    FEMS Immunol Med Microbiol 39:69-72. 2003
    ..In conclusion, the FNAB technique is suited to investigate the intrahepatic immune response during chronic hepatitis B infection on a frequent basis...
  82. doi request reprint Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections
    Bi Sheng Liu
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    J Leukoc Biol 89:981-8. 2011
    ..This suggests that there is no overall increased susceptibility to pathogens but a specific suppression of the functionality of TLR4 signaling pathway in monocytes, which is, at least partly, mediated via IL-10...
  83. ncbi request reprint Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis
    Emile L E de Bruijne
    Department of Hematology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Thromb Haemost 97:181-5. 2007
    ..In conclusion, genetic variation in the TAFI gene is associated with risk of SVT, suggesting a role for TAFI in the pathogenetic mechanism of SVT...
  84. doi request reprint Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences
    Jasper H Smalberg
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Arterioscler Thromb Vasc Biol 31:485-93. 2011
    ..These clear differences in underlying risk factors provide leads for further research on the site specificity of venous thrombosis and the development of thrombosis at these distinct sites...
  85. ncbi request reprint Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B
    Renate G van der Molen
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Hepatology 40:738-46. 2004
    ..In conclusion, mDC and pDC are functionally impaired in patients with chronic hepatitis B. This might be an important way by which hepatitis B virus evades an adequate immune response, leading to viral persistence and disease chronicity...
  86. pmc Retention of CD4+ CD25+ FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans
    Mark A A Claassen
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Virol 85:5323-30. 2011
    ..These findings provide important insight into the dynamics of the immune response to HCV, as well as the effect of therapy on intrahepatic immunity...
  87. ncbi request reprint [Non-cirrhotic portal hypertension: rare cause of upper gastrointestinal bleeding]
    Jeoffrey N L Schouten
    afd Maag, Darm en Leverziekten, Erasmus Medisch Centrum Rotterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A1276. 2010
    ..When portal hypertension occurs in association with patent portal and hepatic veins, and in the absence of liver cirrhosis, NCPH must be considered. The prognosis of this disease is much better than that of cirrhosis...
  88. doi request reprint Prospects of RNAi and microRNA-based therapies for hepatitis C
    Qiuwei Pan
    Erasmus MC University Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam 3015 CE, The Netherlands
    Expert Opin Biol Ther 9:713-24. 2009
    ..RNA interference (RNAi) represents a promising new approach to combat viral infections, and recent developments in the field of gene therapy have increased the feasibility of clinical applications...
  89. pmc The Rotterdam Study: 2010 objectives and design update
    Albert Hofman
    Department of Epidemiology, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam The Netherlands
    Eur J Epidemiol 24:553-72. 2009
    ..epib.nl/rotterdamstudy). This article gives the rationale of the study and its design. It also presents a summary of the major findings and an update of the objectives and methods...
  90. ncbi request reprint Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C
    Bart J Veldt
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Room Ca 326a, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Hepatol 47:356-65. 2007
    ..The aim of this study was to investigate the safety and the antiviral activity of alpha-galactosylceramide as a novel class of treatment for chronic hepatitis C patients...
  91. ncbi request reprint New therapeutic opportunities for hepatitis C based on small RNA
    Qiu wei Pan
    Erasmus MC University Medical Centre, Department of Gastroenterology, Room L458, sGravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    World J Gastroenterol 13:4431-6. 2007
    ..In particular, we will focus on the newly defined role of cellular microRNA (miR-122) in viral replication and discuss its potential for HCV molecular therapy...
  92. doi request reprint Role of T cell immunity in hepatitis C virus infections
    Mark A A Claassen
    Liver Unit, Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
    Curr Opin Virol 3:461-7. 2013
    ....
  93. doi request reprint A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients
    Theodora E M S de Vries-Sluijs
    Department of Internal Medicine Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands
    J Infect Dis 203:984-91. 2011
    ..The primary and secondary aims of our study were to investigate the effectiveness and compliance of 2 different vaccination regimen in an HIV-infected population...
  94. doi request reprint IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression
    Bi Sheng Liu
    Department of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center Rotterdam, s Gravendijkwal 230, Rotterdam, The Netherlands
    Blood 117:2385-95. 2011
    ..Our findings on the differences between IFNα and IL-29 in modulating TLR-induced cytokine production by macrophages may contribute to understanding the role of IFNs in regulating immunity to pathogens...
  95. doi request reprint Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study
    Jildou Hoekstra
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    J Hepatol 51:696-706. 2009
    ..PNH is an acquired disorder of hematopoietic stem cells, characterized by intravascular hemolysis and venous thrombosis. Testing for this hematological disorder should be considered in all BCS patients...
  96. doi request reprint Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome
    Sarwa Darwish Murad
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Liver Int 28:249-56. 2008
    ..The clinical outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt (TIPS) for patients with Budd-Chiari syndrome (BCS) is as yet largely unknown...
  97. ncbi request reprint Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients
    Hans J J van der Vliet
    Department of Internal Medicine, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
    Clin Immunol 114:183-9. 2005
    ....
  98. ncbi request reprint Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen
    Dave Sprengers
    Department of Dermatology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 134:2132-43. 2008
    ..We here describe a role for V alpha14 iNKT cells in modulating conventional T-cell responses to antigen expressed in liver, using transferrin-mOVA (Tf-mOVA) mice...
  99. ncbi request reprint Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection
    Jeroen N Stoop
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
    Hepatology 41:771-8. 2005
    ..T(reg) have an immunosuppressive effect on HBV-specific T helper cells. The presence of HBV-specific T(reg) could contribute to an inadequate immune response against the virus, leading to chronic infection...
  100. ncbi request reprint Pegylated interferon-alpha2b and lamivudine in hepatitis B e antigen-positive chronic hepatitis B
    Martijn J ter Borg
    Ann Intern Med 143:391; author reply 391-2. 2005
  101. ncbi request reprint Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
    Jinlin Hou
    Institute of Hepatology, University College London, London WC1E 6HX, UK
    J Med Virol 79:1055-63. 2007
    ..The optimal duration of interferon-based therapies in chronic hepatitis B may vary between different HBV genotypes...